Press release
Strong Growth Ahead: Alzheimer's Disease Diagnostic Market Size To Grow At Arecord 10.7% Cagr By 2029
Alzheimer's Disease Diagnostic
How Big Is the Alzheimer's Disease Diagnostic Market Size Expected to Be by 2034?
The market size for diagnosing Alzheimer's disease has seen rapid expansion in recent years. The expected growth is from $6.56 billion in 2024 to $7.28 billion in 2025, with a compound annual growth rate (CAGR) of 11%. This significant increase over the historical period can be tied to factors such as increased incidence of Alzheimer's disease and dementia, escalating awareness regarding the need for early prognosis for effective management, technological advancements in imaging methodologies like MRI and PET scans, heightened investment in research and development dealing with neurodegenerative diseases, as well as government interventions and financial support for Alzheimer's research and diagnosis.
The market size for diagnosing Alzheimer's disease is projected to experience a substantial increase over the upcoming years. It is anticipated to reach $10.91 billion by 2029, showing a compound annual growth rate (CAGR) of 10.7%. The expected expansion during the forecast period can be linked to factors such as the advancement in blood-based biomarkers for non-intrusive diagnosis, the surge for personalized and precision diagnostics, the incorporation of artificial intelligence and machine learning in early detection tools, the increasing use of digital health technologies for remote monitoring and diagnosis, and the enlargement of health infrastructure in emerging markets to enhance accessibility. The forecasted period will also witness significant trends like the rise of diagnostic approaches that blend imaging, biomarkers, and cognitive tests, a heightened emphasis on point-of-care diagnostic solutions for quicker results, the creation of wearable devices for constant cognitive health monitoring, growing synergy between biotech firms and research institutions for novel solutions, and the expansion in direct-to-consumer genetic testing for assessing Alzheimer's risk.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21093
What Are the Emerging Segments Within the Alzheimer's Disease Diagnostic Market?
The alzheimer's disease diagnostic market covered in this report is segmented -
1) By Type: Triage, Diagnosis, Screening
2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests
3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center
Subsegments:
1) By Triage: Cognitive Testing, Imaging Techniques
2) By Diagnosis: Biomarker Testing, Neuroimaging
3) By Screening: Neuropsychological Testing, Genetic Testing
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp
What Long-Term Drivers Are Shaping Alzheimer's Disease Diagnostic Market Trends?
The surge in chronic illnesses is anticipated to fuel the expansion of the alzheimer's disease diagnostic market. Chronic illness, a health problem lasting more than three months, is escalating due to several closely interlinked factors, such as lifestyle choices, environmental factors, genes, and social-economic conditions. Chronic conditions like heart problems, diabetes, and high blood pressure enhance the likelihood of developing Alzheimer's disease (AD) and other kinds of dementia. As per the American Heart Association Inc.'s report in January 2022, there may be up to 9.3 million cases of brain disorders in the US by 2060. The existing number is increasing rapidly in the US, and one out of six people across the globe already has a brain disorder. The global count of brain disorders is expected to hit 1 billion by 2021. Thus, the rise in chronic illnesses is expected to boost the alzheimer's disease diagnostic market.
Who Are the Top Competitors in Key Alzheimer's Disease Diagnostic Market Segments?
Major companies operating in the alzheimer's disease diagnostic market are Pfizer Inc., AbbVie, Bristol Myers Squibb Company, Hoffmann-La Roche, Eli Lilly and Company, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Daiichi Sankyo Co., Sysmex, Lantheus, Quanterix, FujireBio, TauRx Pharmaceuticals Ltd, AC Immune, C2N diagnostics, AXON Neuroscience, Neuro-Bio Ltd, Anavex Life Sciences Corp., Treventis Corporation
What Alzheimer's Disease Diagnostic Market Trends Are Gaining Traction Across Different Segments?
Leading firms in the Alzheimer's disease diagnostic market are concentrating on improving blood-based biomarker tests, an advancement expected to streamline the diagnostic process for Alzheimer's disease. It could lessen the need for invasive procedures and increase access to prompt treatment for patients. In October 2023, Quanterix, an American biotech research firm, introduced the LucentAD p-Tau 217 test, a blood biomarker that can accurately detect Alzheimer's pathology. Traditional methods of detecting cerebrospinal fluid (CSF) biomarkers, such as positron emission tomography (PET) or lumbar puncture, are expensive, invasive, and not universally accessible. Additionally, Quanterix has combined its highly sensitive SimoaÒ technology with the proven p-Tau 217 antibodies from J&J Innovative Medicine, resulting in exceptional accuracy and a simplified procedure.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report
Which Regions Are Becoming Hubs for Alzheimer's Disease Diagnostic Market Innovation?
North America was the largest region in the alzheimer's disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer's disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Alzheimer's Disease Diagnostic Market?
2. What is the CAGR expected in the Alzheimer's Disease Diagnostic Market?
3. What Are the Key Innovations Transforming the Alzheimer's Disease Diagnostic Industry?
4. Which Region Is Leading the Alzheimer's Disease Diagnostic Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Strong Growth Ahead: Alzheimer's Disease Diagnostic Market Size To Grow At Arecord 10.7% Cagr By 2029 here
News-ID: 4069571 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Alzheimer
Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928
Key Takeaways
• Disease-modifying…
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
